BE897227A - Traitement des troubles allergiques - Google Patents
Traitement des troubles allergiques Download PDFInfo
- Publication number
- BE897227A BE897227A BE1/10828A BE1010828A BE897227A BE 897227 A BE897227 A BE 897227A BE 1/10828 A BE1/10828 A BE 1/10828A BE 1010828 A BE1010828 A BE 1010828A BE 897227 A BE897227 A BE 897227A
- Authority
- BE
- Belgium
- Prior art keywords
- treatment
- allergic
- immunoglobulin
- intact
- use according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 16
- 230000000172 allergic effect Effects 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 14
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 14
- 238000001802 infusion Methods 0.000 claims abstract description 11
- 238000001990 intravenous administration Methods 0.000 claims abstract description 9
- 230000020477 pH reduction Effects 0.000 claims abstract description 3
- 210000002966 serum Anatomy 0.000 claims abstract description 3
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 4
- 206010052613 Allergic bronchitis Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 206010028164 Multiple allergies Diseases 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 201000009961 allergic asthma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8220235 | 1982-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE897227A true BE897227A (fr) | 1984-01-06 |
Family
ID=10531629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE1/10828A BE897227A (fr) | 1982-07-13 | 1983-07-06 | Traitement des troubles allergiques |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5931716A (it) |
| BE (1) | BE897227A (it) |
| IT (1) | IT1237341B (it) |
| PH (1) | PH20047A (it) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200353081A1 (en) * | 2018-01-05 | 2020-11-12 | Network Immunology Inc. | A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8406560D0 (en) * | 1984-03-13 | 1984-04-18 | Central Lab Of The Blood Donor | Organic compounds |
-
1983
- 1983-07-06 BE BE1/10828A patent/BE897227A/fr not_active IP Right Cessation
- 1983-07-11 PH PH29205A patent/PH20047A/en unknown
- 1983-07-12 IT IT8348665A patent/IT1237341B/it active
- 1983-07-12 JP JP58127528A patent/JPS5931716A/ja active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200353081A1 (en) * | 2018-01-05 | 2020-11-12 | Network Immunology Inc. | A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases |
| EP3735273A4 (en) * | 2018-01-05 | 2021-11-17 | Network Immunology Inc. | COMBINATION OF A PLASMATIC IMMUNOGLOBULIN AND A SPECIFIC ANTIGEN IMMUNOGLOBULIN FOR IMMUNE SYSTEM MODIFICATION AND THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES |
| US12090202B2 (en) | 2018-01-05 | 2024-09-17 | Network Immunology Inc. | Combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| IT8348665A0 (it) | 1983-07-12 |
| PH20047A (en) | 1986-09-11 |
| IT1237341B (it) | 1993-05-31 |
| JPS5931716A (ja) | 1984-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sopori et al. | Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms | |
| Slavin et al. | A pathologic study of allergic bronchopulmonary aspergillosis | |
| Faustino et al. | Regulatory T cells migrate to airways via CCR4 and attenuate the severity of airway allergic inflammation | |
| Pepys | The Relationship of Nonspecific and Specific Factors in the Tuberculin Reaction, A Review | |
| Ring et al. | Anaphylactoid reactions to infusions of plasma protein and human serum albumin Role of aggregated proteins and of stabilizers added during production | |
| US4234569A (en) | Production of aldehyde-treated allergen-containing substances | |
| DK175473B1 (da) | Antiinflammatorisk faktor, fremgangsmåde til isolation og anvendelse heraf | |
| Sato et al. | Immunotherapy in food allergy: towards new strategies | |
| Lange et al. | Steroid therapy of systemic lupus erythematosus based on immunologic considerations | |
| BE1011033A6 (fr) | Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer. | |
| EP2358391B1 (fr) | Utilisation d'un concentre d'immunoglobulines g (igg) appauvri en anticorps anti-a et anti-b pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo | |
| Aronson et al. | Passive transfer of experimental allergic uveitis | |
| Henz et al. | Causes of urticaria | |
| BE897227A (fr) | Traitement des troubles allergiques | |
| RUBIN et al. | Susceptibility to subacute thyroiditis is genetically influenced: familial occurrence in identical twins | |
| JP7754810B2 (ja) | 肝臓再生に使用するための血漿画分 | |
| FR2657784A1 (fr) | Facteur endogene cerebral, procede d'obtention et applications therapeutiques et diagnostiques. | |
| FR2555755A1 (fr) | Procede de dosage des immunoglobulines humaines qui sont specifiques d'antigenes cancereux humains et application de ce procede dans le serodiagnostic de maladies tumorales primitives | |
| EP0099775B1 (fr) | Application du N-(diéthylaminoéthyl) 2-méthoxy-5-méthylsulfonyl benzamide dans l'inhibition de la tryptophane pyrrolase | |
| Chauhan et al. | Hypersensitivity | |
| Mathias et al. | Immunoglobulin E antibodies enhance pulmonary inflammation induced by inhalation of a chemical hapten | |
| Kataria et al. | Immune thrombocytopenia and cerebral venous sinus thrombosis following COVID-19 vaccination: a case report | |
| Jakobowicz et al. | Group A blood incompatibility due to the development of apparent anti‐A1 antibodies in a patient of subgroup A2 | |
| EP1320552B1 (fr) | Procede de production d'immunoglobulines anti-thymocytes humains | |
| WO1986005099A1 (fr) | Preparations d'immunoglobulines presentant des titres eleves en anticorps bloquants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: SCHWEIZERISCHES ROTES KREUZ Effective date: 19870731 |